On May 15, 2025,TongEye MedPharm Co., Ltd.announced an important strategic cooperation with Porton Advanced Co., Ltd. At the meeting, Professor Xu Guotong, Founder and Chief Scientist of TongEye MedPharm, and Chen Hui, Deputy General Manager of Porton Advanced and Chief Financial Officer of Porton Advanced, jointly signed the cooperation agreement. According to the agreement, Porton Advanced will be responsible for the full-process technical services such as CMC development and IND application support for TongEye MedPharm’s iPSC-differentiated retinal pigment epithelium (RPE) cell therapy product pipeline. The two sides will work together to promote the clinical transformation of innovative therapies for ophthalmic diseases.
TongEye MedPharm has established an efficient induced differentiation technology platform with independent intellectual property rights, targeting the huge potential of iPSC-derived RPE cell therapy in the treatment of blinding eye diseases such as age-related macular degeneration (AMD). Preclinical studies have confirmed the safety and functionality of its products, and the company has accumulated rich achievements in the research of retinal disease pathogenesis and the development of innovative therapies.
In this cooperation, Porton Advanced will leverage its extensive project experience and technical advantages in the fields of iPSC and cell therapy to provide Porton Advanced with comprehensive services, including iPSC reprogramming and banking, process optimization for RPE directional differentiation, GMP production of RPE final products, quality research, and IND application support.
This collaboration combines the technical strength and rich project experience of professional CDMO enterprises like Porton Advanced in the iPSC field with TongEye MedPharm’s deep technical accumulation and efficient, stable RPE differentiation process. It is believed that this cooperation will better leverage the respective advantages of both parties to overcome key technical challenges in the development of iPSC cell therapy drugs, accelerate the R&D process of innovative ophthalmic cell therapy drugs, and promote the early application of this innovative therapy to benefit a wide range of patients.
About Porton Advanced
Porton Advanced Co., Ltd. was founded in December 2018, based in Suzhou and relying on the listed company BBT Group (Stock Code: 300363). It provides global customers with one-stop service solutions throughout the entire lifecycle of gene and cell therapy drugs, from preclinical research to drug marketing.
Porton Advanced has established CRO and CDMO platforms for plasmids, viral vectors, cell therapy, gene therapy, nucleic acid therapy, etc. It owns a R&D and production base with a total area of over 20,000 m², 10 viral vector production lines, 12 GMP cell therapy production lines (including 2 positive production workshops), and hundreds of clean workshops.
Up to now, Porton Advanced has assisted customers in obtaining 18 clinical approvals worldwide, covering countries such as China, the United States, and New Zealand. It has 5 cell therapy projects in clinical Phase I/II and has successfully helped multiple overseas projects transform to China.
相关新闻
- Tongeye won the first prize in the final of the 2024 “Tianjiaowan Cup” Innovation and Entrepreneurship Competition – Life and Health Track.
- Youqi Biotech won the Innovation Breakthrough Award at the “Digital and Intelligent Health” Industry Collaborative Promotion Conference in Putuo District.
- Reshaping Vision and Leading the New Paradigm of Ophthalmic Treatment: The 2025 Symposium on Clinical Transformation of Ophthalmic CGT Was Successfully Held
- Tongeye won the fourth place in the “National Competition of the China Innovation and Entrepreneurship Competition in the Field of Biomedicine”.
